CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0494 (clinicaltrials.gov NCT No: NCT00849654)
Title:Phase I Dose-Escalation Study of Bruton’s Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Principal Investigator:Nathan Fowler
Treatment Agent:PCI-32765
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of PCI-32765 that can be given to patients with recurrent B-cell lymphoma.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I
Treatment Agents:PCI-32765
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Pharmacyclics, Inc.
Return Visit:At the beginning of each cycle, then every 2-3 months until the participant has
disease progression for a maximum of 6 months.
Home Care:The study drug will be taken at home.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nathan Fowler
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults